The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
MGMT-Independent Temozolomide Resistance in Pediatric Glioblastoma Cells Associated with a PI3-Kinase–Mediated HOX/Stem Cell Gene Signature
Open accessAbstract
Sensitivity to temozolomide is restricted to a subset of glioblastoma patients, with the major determinant of resistance being a lack of promoter methylation of the gene encoding the repair protein DNA methyltransferase MGMT, although other mechanisms are thought to be active. There are, however, limited preclinical data in model systems derived from pediatric glioma patients. We screened a series of cell lines for temozolomide efficacy in vitro, and investigated the differential mechanisms of resistance involved. In the majority of cell lines, a lack of MGMT promoter methylation and subsequent protein overexpression were linked to temozolomide resistance. An exception was the pediatric glioblastoma line KNS42. Expression profiling data revealed a coordinated upregulation of HOX gene expression in resistant lines, especially KNS42, which was reversed by phosphoinositide 3-kinase pathway inhibition. High levels of HOXA9/HOXA10 gene expression were associated with a shorter survival in pediatric high-grade glioma patient samples. Combination treatment in vitro of pathway inhibition and temozolomide resulted in a highly synergistic interaction in KNS42 cells. The resistance gene signature further included contiguous genes within the 12q13-q14 amplicon, including the Akt enhancer PIKE, significantly overexpressed in the KNS42 line. These cells were also highly enriched for CD133 and other stem cell markers. We have thus shown an in vitro link between phosphoinositide 3-kinase–mediated HOXA9/HOXA10 expression, and a drug-resistant, progenitor cell phenotype in MGMT-independent pediatric glioblastoma. Cancer Res; 70(22); 9243–52. ©2010 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Cited by
HOX genes and their role in the development of human cancers
Bhatlekar, S., Fields, J. Z., & Boman, B. M. (2014) · Journal of Molecular Medicine · doi:10.1007/s00109-014-1181-y · Cited by 380
Paugh, B. S., Broniscer, A., Qu, C., Miller, C. P., Zhang, J., Tatevossian, R. G., Olson, J. M., Geyer, J. R., Chi, S. N., da Silva, N. S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.5677 · Cited by 320
Histone H3.3 Mutations Drive Pediatric Glioblastoma through Upregulation of MYCN
Bjerke, L., Mackay, A., Nandhabalan, M., Burford, A., Jury, A., Popov, S., Bax, D. A., Carvalho, D., Taylor, K. R., Vinci, M., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0426 · Cited by 318
Self-citationKitange, G. J., Mladek, A. C., Carlson, B. L., Schroeder, M. A., Pokorny, J. L., Cen, L., Decker, P. A., Wu, W., Lomberk, G. A., Gupta, S. K., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0560 · Cited by 151
Chemical approaches to targeting drug resistance in cancer stem cells
Sotiropoulou, P. A., Christodoulou, M. S., Silvani, A., Herold-Mende, C., & Passarella, D. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.05.002 · Cited by 100
Metadata
- Authors
- Gaspar, N., Marshall, L., Perryman, L., Bax, D. A., Little, S. E., Viana-Pereira, M., Sharp, S. Y., Vassal, G., Pearson, A. D. J., Reis, R. M., Hargrave, D., Workman, P., & Jones, C.
- Venue
- Cancer Research
- Published
- 2010-11-14
- Volume
- 70
- Issue
- 22
- Pages
- 9243-9252
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2142647376
- Cited by
- 163
- References
- 3
- FWCI
- 5.05
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: MGMT-Independent Temozolomide Resistance in Pediatric Glioblastoma Cells Associated with a PI3-Kinase–Mediated HOX/Stem Cell Gene Signature. https://app.cochat.ai/papers/10.1158/0008-5472.can-10-1250
- The paper
- Gaspar, N., Marshall, L., Perryman, L., Bax, D. A., Little, S. E., Viana-Pereira, M., Sharp, S. Y., Vassal, G., Pearson, A. D. J., Reis, R. M., Hargrave, D., Workman, P., & Jones, C. (2010). MGMT-Independent Temozolomide Resistance in Pediatric Glioblastoma Cells Associated with a PI3-Kinase–Mediated HOX/Stem Cell Gene Signature. Cancer Research. https://doi.org/10.1158/0008-5472.can-10-1250
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.